About Us

Bringing together scientific excellence and drug development expertise to deliver breakthrough oral therapies

Home » About Us

Who we are

Entera is a global leader in oral peptide therapeutics.

The Company focuses on significant unmet medical needs where a once daily oral tablet of a peptide treatment or replacement therapy holds the potential to transform the standard of care.

Backed by strong clinical evidence and a solid intellectual property portfolio, Entera has developed the N-Tab platform – an innovative solution that combines peptide stabilization in the GI tract with enhanced systemic absorption. This technology enables first-in-class oral therapies designed for improved patient adherence and better health outcomes.

Driven by a seasoned team of industry experts, Entera is uniquely positioned to advance the next generation of oral peptide therapeutics.

Management Team

Miranda Toledano, Board Member and Chief Executive Officer

Miranda Toledano has served as a member of our Board of Directors since 2018, as prior Chair of the Audit Committee and Member of the Scientific Advisory Committee. Ms. Toledano has served as Entera’s Chief Executive Officer since July 2022. Ms. Toledano has over 25 years of C-level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Board Member of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009, tovecimig) and led strategic execution, including a $117 million China License Transaction and TRIGR’s 2021 acquisition by Compass. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Rachel B. Wagman, MD, FACE, FACP, Chief Clinical Advisor

Dr. Wagman has served as Entera’s Chief Clinical Advisor since 2024. Dr. Wagman brings over 20 years of career success across the biopharmaceutical industry with a focus on metabolic bone disease and women’s health. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management. Dr. Wagman’s clinical leadership experiences include progressive roles at Eli Lilly, Amgen, and Myovant Sciences, where as Senior Vice President Clinical Development, she integrated Myovant’s development portfolio into the newly-established Sumitomo Pharma America. She completed her BA at the University of Pennsylvania, MD at Jefferson Medical College, Internal Medicine residency at Thomas Jefferson University Hospital, and postdoctoral fellowship in Endocrinology, Gerontology, and Metabolism at Stanford University School of Medicine. She is a Fellow of both the American College of Endocrinology and the American College of Physicians and holds dual board certifications in Internal Medicine and Endocrinology, Diabetes, and Metabolism.

Gregory Burshtein, PhD, Chief of Research and Development

Dr. Burshtein has led research and development at the Company since he joined Entera in September 2012, as Director of Pharmaceutical R&D, and since May 2024, as our Chief of Research and Development. Dr. Burshtein is a leader in the field of oral delivery of peptides, has published in peer-reviewed journals, and holds 25 issued patents and has 113 pending patent applications related to development, formulation, and delivery of oral large molecules. Dr. Burshtein holds over 20 years of experience in the field of drug delivery, pharmacology and biopharmaceutics, with a primary focus on the challenging area of oral delivery of therapeutic peptides. Dr. Burshtein obtained his PhD in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of the Hebrew University of Jerusalem.

Dana-Garbeli Yaacov, CPA, Chief Financial Officer

Dana Yaacov-Garbeli has served as our Chief Financial Officer since June 2019. Ms. Yaacov-Garbeli has over 17 years of finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She has significant experience in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.

Leslie Gautam, Chief Business Officer

On May 8th, 2025, Leslie Gautam joined Entera as Chief Business Officer. Leslie has extensive strategic advisory experience across biopharma, with transaction experience in both clinical and commercial stage companies with a particular focus on women’s health and supportive care. Most recently, Leslie was Co-Founder CEO of an early stage women’s health company that provided care delivery and innovation for patients with hyperemesis gravidarum. Prior to this role, Leslie held senior positions in the healthcare investment banking team at Stifel and Houlihan Lokey. Previously, she served as part of the business development teams at Purdue Pharma and Noven Pharmaceuticals and was an Institutional Investor ranked equity research analyst for UBS covering the pharmaceutical sector. Leslie started her career in the healthcare investment banking group of BMO Capital Markets. Leslie holds a B.S. in Psychobiology and Computer Programming from UCLA and an MBA in Finance from Columbia Business School.

Hillel Galitzer, PhD, Chief Operating Officer

Dr. Galitzer has served as our Chief Operating Officer since February 2014, prior to which he served as a Director of Scientific Development from July 2010. Prior to joining Entera, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of Optivasive Inc. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.

Scientific Advisory Board

Felicia Cosman, MD, SAB Chair

Dr. Cosman is Professor of Medicine at Columbia University and a clinical scientist renowned for her work on anabolic therapies and treatment sequencing in osteoporosis. Co‑Editor‑in‑Chief of Osteoporosis International since 2016, she has authored more than 190 peer‑reviewed papers and 50 book chapters, led pioneering teriparatide studies (including combination and sequential regimens), and served as principal investigator for trials of abaloparatide and romosozumab. Her contributions earned the ACE Distinction in Endocrinology (2019) and the ASBMR Bartter Award (2020). She holds a BA from Cornell, an MD from Stony Brook, and completed residency and fellowship at Columbia.

Steven R. Goldstein, MD

A Professor of Obstetrics & Gynecology at NYU Grossman School of Medicine, Dr. Goldstein is immediate past President of the International Menopause Society and former President of NAMS. He has written seven women’s‑health books, over 140 research articles, and the IMS white paper on bone health, and has delivered 400+ invited lectures worldwide. Honors include the 2023 William J. Fry Memorial Lecture (AIUM) and Ian Donald Gold Medal (ISUOG) and the 2016 NAMS Clarkson Award, reflecting his leadership in menopause, ultrasound, and mid‑life bone care.

John P. Bilezikian, MD, PhD

The Dorothy L. and Daniel H. Silberberg Professor of Medicine at Columbia University, Dr. Bilezikian is Vice‑Chair for International Education & Research and Chief, Emeritus, of Endocrinology. A past President of ASBMR and ISCD, he has edited flagship journals (JCEM, JBMR) and seminal textbooks, co‑chaired every International Parathyroid Workshop since 2002, and published over 935 papers on parathyroid disorders, vitamin D, and osteoporosis. His accolades span the Endocrine Society Distinguished Physician Award, ASBMR’s three highest honors, and Columbia’s 2019 Gold Medal for Research

Maria Luisa Brandi, MD, PhD

Professor Emerita of Endocrinology at the University of Florence, Prof. Brandi is a globally cited expert in metabolic bone diseases with 930+ publications. She directs the Italian foundations F.I.R.M.O. and O.F.F. Italia, sits on the IOF Board, chairs the IOF Academy on Skeletal Rare Diseases and Capture the Fracture®, and serves on ESCEO’s Board. Her clinical and policy leadership—from Italy’s Ministry of Health to EU rare‑bone networks—has shaped international guidelines, earning her numerous awards and a top‑ten citation ranking in osteoporosis research

Bente Langdahl, MD, PhD

Bruce Mitlak, MD

Former Chief Medical Officer of Radius Health and Distinguished Medical Fellow at Eli Lilly, Dr. Mitlak spent two decades advancing musculoskeletal and women’s‑health therapeutics, notably for osteoporosis. Trained in Internal Medicine and Endocrinology at Harvard Medical School, he has authored 100+ publications—including in NEJM, JAMA, and The Lancet—that underpin several approved bone‑health treatments

Serge Ferrari, MD, PhD

Professor of medicine, Head of the Clinical Service and Research Laboratory of Bone Diseases, Vice-Dean for translational research and innovation at the Geneva Faculty of Medicine and University Hospital, Switzerland

Rogely Boyce, DVM, PhD, DACVP

Dr. Boyce is a well-recognized independent expert with a broad expertise in the field of bone toxicologic pathology. She is a DVM PhD and is a diplomate of the American College of Veterinary Pathology -DACVP specializing in metabolic bone diseases, arthritis, and orthopedics. She has over 35 years of experience in this field and has held several positions in pharmaceutical companies and CROs and is therefore familiar with the drug development process and interaction with regulatory authorities. Dr. Boyce is a member of the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) group for skeletal tissues, co-author of several book chapters and over 70 publications on bone histopathology or other scientific topics in peer reviewed journals. She also led several meeting sessions on safety considerations of bone therapeutics. For instance, she was the nonclinical expert involved in the meetings in etidronate, denosumab and romosozumab. She participated in FDA committee meetings for etidronate, calcitonin and romosozumab and assisted with preparations for the FDA Advisory committee meeting for denosumab. In addition, she contributed to several nonclinical safety sections in IND, NDA and BLA filings. Dr. Boyce currently runs her own independent consultancy company Beechy Ridge ToxPath LLC based in North Carolina (USA).

Board of Directors

Gerald Lieberman, Chairman

Gerald Lieberman has served as a member of our Board since April 2014 and became our Chairman in July 2019. Mr. Lieberman is also a member of the board of directors of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals and the world’s largest generic drug developer and manufacturer, where he chairs the Audit Committee and serves on both the Human Resources and Compensation Committee and the Finance Committee. He also serves as Chairman of the Board of Directors of DosenRx, Ltd., a Digital health company that has developed a personalized, patient-controlled device for delivering medication. He is also currently a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at Alliance Bernstein L.P., where he served as President and Chief Operating Officer from 2004 to 2009, as Chief Operating Officer from 2003 to 2004 and as Executive Vice President, Finance and Operations from 2000 to 2003. From 1998 to 2000, he served as Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc., until it was acquired by Alliance Capital in 2000, forming Alliance Bernstein L.P. Prior to that, he served in various executive positions at Fidelity Investments and at Citicorp. Prior to joining Citicorp he was a certified public accountant with Arthur Andersen. He previously served on the board of directors of Forest Laboratories, LLC from 2011 to 2014, Computershare Ltd. from 2010 to 2012 and Alliance Bernstein L.P. from 2004 to 2009.

Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business from the University of Connecticut.

Miranda Toledano

Sean Ellis

Sean Ellis has served as a member of our Board since June 2019. Mr. Ellis brings extensive knowledge of both life sciences and the U.S. financial markets, with a longstanding history in asset management. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and related healthcare industries. Centillion is one of Entera Bio’s earliest investors and largest shareholders.

He holds a BA from New York University and MBA from Columbia University.

Haya Taitel

Ms. Taitel has over 30 years of global C-level biopharma commercial and strategic executive experience. Ms. Taitel currently serves as the Head of Sanofi’s Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock®, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led Kadmon Board’s Executive Commercial Committee. Beginning in 1997, Ms. Taitel had held various commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women’s healthcare.

Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.

Gerald M. Ostrov

Gerald M. Ostrov has served as a member of our Board since January 2019. Mr. Ostrov consults and invests in new technologies in the medical device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including Mother’s Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo, a developer of next generation baby and mother health monitoring for both hospital and home use. From 2008 to 2010, he served as Chairman and CEO of Bausch & Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch & Lomb following its going-private transaction. From 1998 until 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson & Johnson’s Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson & Johnson and quickly rose to serve as Company Group Chairman of the Consumer and Personal Care businesses in North America. From 1982 to 1991, he served as President of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson & Johnson. From 1973 to 1976, Mr. Ostrov worked at Procter & Gamble.

Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard.

Yonatan Malca

Yonatan Malca has served as a member of our Board since 2011. Mr. Malca currently serves as a Chief Executive Officer and director of NanoGohst Ltd. Since 2010 until 2021, he served as a Chief Executive Officer and director of D.N.A Biomedical Mr. Malca also serves as a director of Nextgen-Biomed LTD. (TASE:NXGN) and Jungo Connectivity Ltd. (TASE:JNGO) , each of which is an Israeli public company.

Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel.